Pancreatic ductal adenocarcinoma (PDAC) is characterized clinically by poor survival and mechanistically by KRAS- and autophagy-dependent growth. We and others previously demonstrated that inhibition ...

Avutometinib plus defactinib granted priority review by FDA, under the accelerated approval pathway, for recurrent KRAS mutant LGSOC; PDUFA action date set for June 30, 2025 Potential U.S. commercial ...

In this episode Nadine chats to PTX CEO James McDonnell to unpack PTX-100, a first-in-class cancer therapy targeting the RAS ...

Verastem Oncology Inc. and Genfleet Therapeutics Ltd. have inked a discovery and development deal to advance three oncology discovery programs targeting RAS pathway-driven cancers. The collaboration ...

Promising early clinical data about the drugs ERAS-007 and ERAS-601 has led to a trial studying the combination of the two drugs in treating patients with RAS/MAPK pathway-driven cancers. The first ...

The Ras/mitogen-activated protein kinase (MAPK) pathway is a central signalling cascade that transmits extracellular growth and differentiation cues to nuclear effectors. Germline mutations in ...

A drug that targets a molecular pathway involved in many types of cancer extends survival rate of pancreatic cancer patients by more than a year on average, according to new results from a clinical ...

This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting I. This abstract does not include a full text component.

ADC is cleared for clinical development. Designed to selectively deliver pan-RAS(ON) inhibition to tumors while minimizing systemic toxicity. IND submis ...

We recently determined that concurrent inhibition of autophagy, using the lysosomal inhibitor chloroquine (CQ), and of ERK, using a small molecule ERK inhibitor (ERKi), synergistically suppressed the ...